RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Xenon Pharmaceuticals Stock

Xenon Pharmaceuticals Revenue 2025

Xenon Pharmaceuticals Revenue

5.42 M USD

Ticker

XENE

ISIN

CA98420N1050

WKN

A12ETN

In 2025, Xenon Pharmaceuticals's sales reached 5.42 M USD, a 1,600.08% difference from the 318,750 USD sales recorded in the previous year.

The Xenon Pharmaceuticals Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e854.26-0,70
2028e530.6-1,13
2027e200.65-2,99
2026e41.81-14,35
2025e5.42-110,72
2024e0.32-1882,35
2023--
20229.43-63,63
202118.44-32,54
202032.17-18,65
20196.83-87,85
2018--
20170.31-1935,48
20161.8-333,33
201515.58-38,51
201428.37-21,15
201327.36-21,93
201214.31-41,93
20116.92-86,71

Xenon Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Xenon Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Xenon Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Xenon Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Xenon Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Xenon Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Xenon Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Xenon Pharmaceuticals’s growth potential.

Xenon Pharmaceuticals Revenue, EBIT and net profit per share

DateXenon Pharmaceuticals RevenueXenon Pharmaceuticals EBITXenon Pharmaceuticals Net Income
2029e854.26 M undefined260.7 M undefined179.01 M undefined
2028e530.6 M undefined-3.39 M undefined-5.58 M undefined
2027e200.65 M undefined-279.12 M undefined-200.19 M undefined
2026e41.81 M undefined-363.05 M undefined-302.89 M undefined
2025e5.42 M undefined-323.91 M undefined-279.82 M undefined
2024e318,750 undefined-280.24 M undefined-240.19 M undefined
20230 undefined-214.05 M undefined-182.39 M undefined
20229.43 M undefined-129.14 M undefined-124.94 M undefined
202118.44 M undefined-78.99 M undefined-77.09 M undefined
202032.17 M undefined-31.3 M undefined-28.01 M undefined
20196.83 M undefined-42.82 M undefined-40.03 M undefined
20180 undefined-38.04 M undefined-31.62 M undefined
2017310,000 undefined-32.58 M undefined-30.7 M undefined
20161.8 M undefined-24.82 M undefined-23 M undefined
201515.58 M undefined-9.36 M undefined-15.75 M undefined
201428.37 M undefined11.11 M undefined13.02 M undefined
201327.36 M undefined9.71 M undefined3.83 M undefined
201214.31 M undefined-3.15 M undefined-4.3 M undefined
20116.92 M undefined-12.11 M undefined-11.99 M undefined

Xenon Pharmaceuticals stock margins

The Xenon Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Xenon Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Xenon Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Xenon Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Xenon Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Xenon Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Xenon Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Xenon Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Xenon Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Xenon Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Xenon Pharmaceuticals Margin History

Xenon Pharmaceuticals Gross marginXenon Pharmaceuticals Profit marginXenon Pharmaceuticals EBIT marginXenon Pharmaceuticals Profit margin
2029e0 %30.52 %20.96 %
2028e0 %-0.64 %-1.05 %
2027e0 %-139.11 %-99.77 %
2026e0 %-868.32 %-724.44 %
2025e0 %-5,977.23 %-5,163.62 %
2024e0 %-87,918.51 %-75,352.68 %
20230 %0 %0 %
20220 %-1,369.46 %-1,324.92 %
20210 %-428.36 %-418.06 %
20200 %-97.3 %-87.07 %
20190 %-626.94 %-586.09 %
20180 %0 %0 %
20170 %-10,509.68 %-9,903.23 %
20160 %-1,378.89 %-1,277.78 %
20150 %-60.08 %-101.09 %
20140 %39.16 %45.89 %
20130 %35.49 %14 %
20120 %-22.01 %-30.05 %
20110 %-175 %-173.27 %

Xenon Pharmaceuticals Aktienanalyse

What does Xenon Pharmaceuticals do?

Xenon Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development of innovative therapies for rare diseases. It was founded in 1996 and is headquartered in Burnaby, British Columbia, Canada, with additional offices in the United States and Europe. The company has become a leading biotech company in the industry and focuses on identifying and developing treatments for rare diseases through its proprietary platform called Extreme Genetics. Xenon Pharmaceuticals has a wide pipeline of clinical candidates targeting diseases such as ichthyosis, X-linked adrenoleukodystrophy, pain disorders, and epilepsy. It collaborates with pharmaceutical companies to utilize its platform technology and expertise in the research of rare diseases. Its key drug candidate is XEN496 for the treatment of epilepsy. Overall, Xenon Pharmaceuticals plays a significant role in the biotech industry and continues to make progress in developing innovative therapies for rare diseases. Xenon Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Xenon Pharmaceuticals's Sales Figures

The sales figures of Xenon Pharmaceuticals originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Xenon Pharmaceuticals’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Xenon Pharmaceuticals's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Xenon Pharmaceuticals’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Xenon Pharmaceuticals stock

How much revenue did Xenon Pharmaceuticals generate this year?

Xenon Pharmaceuticals has achieved a revenue of 5.42 M USD this year.

How much was the turnover of the company Xenon Pharmaceuticals compared to the previous year?

The revenue of Xenon Pharmaceuticals has increased by 1,600.08% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Xenon Pharmaceuticals?

The revenue of Xenon Pharmaceuticals is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Xenon Pharmaceuticals measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Xenon Pharmaceuticals so important for investors?

The revenue of Xenon Pharmaceuticals is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Xenon Pharmaceuticals pay?

Over the past 12 months, Xenon Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Xenon Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Xenon Pharmaceuticals?

The current dividend yield of Xenon Pharmaceuticals is .

When does Xenon Pharmaceuticals pay dividends?

Xenon Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Xenon Pharmaceuticals?

Xenon Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Xenon Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Xenon Pharmaceuticals located?

Xenon Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Xenon Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Xenon Pharmaceuticals from 1/17/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/17/2025.

When did Xenon Pharmaceuticals pay the last dividend?

The last dividend was paid out on 1/17/2025.

What was the dividend of Xenon Pharmaceuticals in the year 2024?

In the year 2024, Xenon Pharmaceuticals distributed 0 USD as dividends.

In which currency does Xenon Pharmaceuticals pay out the dividend?

The dividends of Xenon Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Xenon Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Xenon Pharmaceuticals

Our stock analysis for Xenon Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Xenon Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.